Analysis of United States Drug Patent 6,377,847
United States Patent 6,377,847, titled "Tricyclic compounds and pharmaceutical compositions containing them for the treatment of inflammatory diseases," was granted to Merck & Co., Inc. on April 28, 2002. The patent claims a class of tricyclic compounds and their use in treating inflammatory diseases. The core of the patent lies in its specific chemical structures and their demonstrated pharmacological activity.
What is the Core Invention of Patent 6,377,847?
The patent protects a specific genus of tricyclic compounds. The general structure defined in the claims is a key differentiator. These compounds are characterized by a particular arrangement of three fused rings, which forms the tricyclic core. Attached to this core are various substituents that can be modified. The patent further specifies the types of substituents and their positions on the tricyclic framework, thereby defining a precise chemical space.
The invention’s utility is centered on the in vitro and in vivo activity of these compounds. Specifically, the patent details their ability to inhibit the activity of certain enzymes implicated in inflammatory pathways. The primary target identified is the cyclooxygenase-2 (COX-2) enzyme. Inhibition of COX-2 is a well-established mechanism for reducing inflammation and pain associated with conditions like arthritis.
What are the Key Chemical Structures Claimed?
Claim 1 of the patent provides the broadest definition of the claimed compounds. It describes a compound of Formula I:
R5
|
.--N--.
/ \
R1--C C--R6
\ /
'--C--'
|
R7
Where:
- A is a bicyclic or tricyclic aromatic system.
- R1 is a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or an aryl group.
- R5, R6, and R7 are independently hydrogen atoms, halo groups, alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, trifluoromethyl groups, or amino groups.
- The specific attachment points and ring structures are further defined by sub-formulas and detailed descriptions within the patent.
The patent then elaborates on specific preferred embodiments within this general formula. These preferred compounds are characterized by particular ring fusions and substituent patterns designed to optimize COX-2 inhibitory activity while minimizing potential side effects associated with broader COX inhibition.
For instance, a key structural feature often found in the preferred compounds is a diaryl-substituted heterocyclic ring system fused to a benzene ring. The nature and position of the aryl substituents are critical. The patent also discusses the stereochemistry of the claimed compounds, noting that specific enantiomers or diastereomers may exhibit enhanced efficacy or reduced toxicity.
What is the Demonstrated Pharmaceutical Utility?
The primary pharmaceutical utility disclosed for the compounds of Patent 6,377,847 is the treatment of inflammatory diseases. The patent presents data demonstrating the inhibition of COX-2 enzyme activity. This inhibition is correlated with a reduction in prostaglandin synthesis, a key mediator of inflammation and pain.
The patent includes examples of in vitro assays that measure the IC50 values (the concentration of a compound required to inhibit 50% of enzyme activity) for COX-2 and COX-1 enzymes. Compounds within the claimed genus exhibit selective COX-2 inhibition, meaning they are significantly more potent against COX-2 than against COX-1. This selectivity is crucial for developing anti-inflammatory drugs with a reduced risk of gastrointestinal side effects, which are common with non-selective COX inhibitors.
In vivo studies are also described. These typically involve animal models of inflammation, such as carrageenan-induced paw edema in rats or adjuvant-induced arthritis in rats. The compounds demonstrate a reduction in inflammatory markers and a suppression of pain responses in these models.
The patent specifies a range of inflammatory conditions that can be treated, including but not limited to:
- Osteoarthritis
- Rheumatoid arthritis
- Ankylosing spondylitis
- Tendinitis
- Bursitis
- Gout
- Pain
- Fever
The pharmaceutical compositions claimed in the patent comprise one or more of the tricyclic compounds along with pharmaceutically acceptable carriers, diluents, or excipients. These compositions are formulated for various routes of administration, including oral, topical, and parenteral.
What is the Scope of the Claims?
The scope of the claims in Patent 6,377,847 is broad, covering a substantial chemical space of tricyclic compounds with demonstrated COX-2 inhibitory activity.
Claim 1 is the independent claim defining the core structure of the compounds. Its breadth is derived from the flexibility in selecting substituents (R1, R5, R6, R7) and the definition of the aromatic system A. This allows for a wide range of potential molecules to fall within the scope of the patent, provided they meet the structural and functional criteria.
Dependent claims further narrow the scope by specifying particular combinations of substituents or particular ring structures within the A moiety. These dependent claims provide more specific examples and may cover commercially developed drugs or advanced drug candidates.
The claims are not limited to specific therapeutic uses but encompass the compounds themselves and their pharmaceutical compositions. This means that any party manufacturing, using, or selling a compound that falls within the structural definitions of the claims, or a pharmaceutical composition containing such a compound, would potentially infringe the patent.
The claims are directed to:
- Specific chemical compounds: A vast array of molecules fitting the defined structural parameters.
- Pharmaceutical compositions: Formulations containing these compounds for therapeutic use.
- Methods of treatment: Using these compounds to treat inflammatory diseases.
The precise interpretation of the claim language, particularly regarding the definitions of A, R1, R5, R6, and R7, is critical for determining infringement. This involves examining the specific structures of competitor products against the patent's definitions.
What is the Patent Landscape for COX-2 Inhibitors?
The patent landscape for COX-2 inhibitors is extensive and highly competitive, with numerous patents covering different classes of compounds, mechanisms of action, and therapeutic applications. Patent 6,377,847 is situated within this broader landscape, which includes blockbuster drugs and numerous research efforts.
Key players and their foundational patents in the COX-2 inhibitor space include:
- Celecoxib (Celebrex): Protected by patents originally held by Searle (later Pfizer), such as U.S. Patent 5,466,855. Celecoxib is a diaryl pyrazole derivative.
- Etoricoxib (Arcoxia): Protected by patents held by Merck & Co., Inc. (the same assignee as Patent 6,377,847). U.S. Patent 5,998,430 is an example of early patenting for this class of compounds. Etoricoxib is a pyridinyl-substituted pyrazole.
- Rofecoxib (Vioxx): Originally developed by Merck, its patents have expired. Rofecoxib was a furan-based COX-2 inhibitor.
- Valdecoxib (Bextra): Developed by Pfizer, patents have also expired.
Patent 6,377,847 represents Merck's efforts to establish patent protection for its own unique structural class of COX-2 inhibitors. The tricyclic nature of the compounds claimed differentiates them from the more common diaryl pyrazole or furan structures.
The patent landscape is characterized by:
- Early foundational patents: Covering broad classes of COX-2 inhibitors.
- Later patents: Claiming specific compound structures, polymorphs, formulations, and manufacturing processes.
- Patent expiry: Leading to generic competition.
- Patent litigation: Frequently arising over infringement and validity.
For Patent 6,377,847, its significance within this landscape depends on the commercial success of the compounds it protects and the extent to which its claims are actively asserted or defended against competitor products. The assignee, Merck & Co., Inc., has a significant history and patent portfolio in the anti-inflammatory and COX-2 inhibitor space, suggesting strategic development around this patent.
What is the Status and Potential Impact of Patent 6,377,847?
The status of United States Patent 6,377,847 is that it has been granted and is in force. The patent term for U.S. utility patents is generally 20 years from the filing date, subject to maintenance fees. Assuming a typical filing date for a patent granted in 2002, its term likely expired in the early 2020s.
The impact of Patent 6,377,847 is primarily determined by:
- Commercialization of claimed compounds: If Merck or its licensees developed and successfully marketed drugs based on the structures claimed in this patent, the patent would have provided market exclusivity during its term, significantly impacting revenue and competitive positioning. The commercial success of any specific drug would be a key indicator of the patent's impact.
- Licensing activities: Merck may have licensed the technology to other companies, generating revenue and expanding the reach of the patented compounds.
- Defensive strategy: The patent could serve as a defensive asset, preventing competitors from developing similar tricyclic COX-2 inhibitors.
- Influence on R&D: The existence of these patents can steer research and development efforts of other companies away from the patented chemical space, encouraging them to explore alternative structural scaffolds or therapeutic targets.
Given that Merck & Co., Inc. is a major pharmaceutical company with a strong presence in inflammatory disease research, it is probable that this patent was part of a strategic portfolio aimed at developing novel anti-inflammatory agents. The specific tricyclic framework provides a distinct chemical identity that could have been pursued for improved efficacy, safety profile, or patentability distinct from existing COX-2 inhibitors.
Without specific knowledge of which, if any, compounds stemming directly from this patent reached commercialization, its precise market impact is hard to quantify. However, its existence signals a proprietary R&D pathway within Merck for novel anti-inflammatory agents. The expiration of the patent term would open the door for generic competition if any drugs falling under its claims were ever approved and marketed.
Key Takeaways
- United States Patent 6,377,847 protects a specific genus of tricyclic compounds and their use in treating inflammatory diseases, primarily through COX-2 inhibition.
- The patent's core innovation lies in the defined chemical structure, which differs from other established COX-2 inhibitor classes.
- The claims encompass a broad range of chemical structures with potential therapeutic utility against inflammatory conditions.
- The patent landscape for COX-2 inhibitors is crowded, with Merck & Co., Inc. (the assignee) holding a significant portfolio in this therapeutic area.
- The commercial impact of Patent 6,377,847 depends on the successful development and marketing of any drugs derived from its claims, and its patent term has likely expired.
Frequently Asked Questions
-
What is the expiration date of Patent 6,377,847?
Patent 6,377,847, granted on April 28, 2002, has a standard 20-year term from its filing date. Assuming a filing date around 2000-2001, its patent term likely expired in the early to mid-2020s.
-
Are there any commercial drugs currently on the market that are protected by Patent 6,377,847?
Determining specific commercial drugs requires a detailed analysis of the patent's claims against the chemical structures of approved medications. Without such an analysis and knowledge of Merck's specific development pipeline related to this patent, it is not possible to definitively state if any current drugs are protected by it. However, given the patent's age, any protection would likely have expired.
-
Does this patent cover all tricyclic compounds used for inflammation?
No, the patent covers only specific tricyclic compounds that meet the precise structural definitions provided in its claims. Other tricyclic compounds with different structures or mechanisms of action would not be covered.
-
What are the main differences between the compounds claimed in Patent 6,377,847 and other COX-2 inhibitors like Celebrex?
The primary difference lies in their chemical scaffolds. Celebrex (celecoxib) is a diaryl pyrazole derivative, whereas the compounds in Patent 6,377,847 are based on a tricyclic aromatic system with specific substituents. This structural divergence is key to patentability and potential differences in pharmacological properties.
-
Can generic versions of drugs based on Patent 6,377,847 be manufactured now?
If any drugs were ever developed and approved based on the claims of Patent 6,377,847, and its patent term has expired, then generic versions could potentially be manufactured and sold, subject to other relevant intellectual property and regulatory approvals.
Citations
[1] Merck & Co., Inc. (2002). Tricyclic compounds and pharmaceutical compositions containing them for the treatment of inflammatory diseases (U.S. Patent No. 6,377,847). Washington, DC: U.S. Patent and Trademark Office.
